Lonza’s 2025 Biologics Campaign: 3.5:1 ROAS

Lonza’s Digital Strategy: A Competitive Analysis Campaign Teardown

Breaking down a competitor’s digital strategy, especially in a niche like the pharma market, gives you a serious edge. In mid-2025, Lonza, a major manufacturing partner in the pharma and biotech world, kicked off a campaign to cement its top-dog status in biologics manufacturing. We’re tearing down their approach here, looking at what worked and what didn’t. So how exactly did Lonza use its digital playbook to pull ahead in such a tight, regulated space?

Campaign Overview: “Biologics Breakthrough”

Lonza’s “Biologics Breakthrough” campaign was a six-month, $1.2 million push from June to December 2025. The main goal was simple: get more people to recognize Lonza’s biologics manufacturing chops and feed their sales team qualified leads. Secondary goals were to establish Lonza as a thought leader and get people engaging with their deep-dive technical content like whitepapers. They used a mix of channels, but the real muscle was in LinkedIn, programmatic display, and targeted email.

Strategic Pillars and Execution

The strategy basically came down to three things: creating and sharing educational content, finding the right people, and making it easy for them to convert. To get the content part right, Lonza paid for a bunch of new whitepapers and expert interviews that tackled complex topics like new biologics production methods and regulatory headaches. This content was the core of their marketing push.

Getting in front of the right audience happened mostly on LinkedIn’s Campaign Manager. Lonza got super specific, targeting job titles like “Head of Biologics Development,” “VP of Manufacturing,” and “Chief Scientific Officer” inside pharma and biotech companies with more than 500 employees. They focused geographically on the big pharma hubs in North America and Europe. For their programmatic display ads, run through The Trade Desk, they built lookalike audiences from their own customer lists and website traffic, then served ads on niche industry sites and scientific journals.

To optimize the conversion path, they built dedicated landing pages for each piece of content with obvious CTAs to either download the asset or request a consultation. Once someone downloaded something, they were dropped into an automated email sequence designed to move them through the sales process.

Creative Approach and Messaging

The creative strategy was all about establishing authority and scientific credibility. The ad copy talked up Lonza’s deep experience and top-tier facilities. The visuals were clean and professional, think pristine labs, high-tech machines, and scientific diagrams. A series of short video testimonials from their own scientists talking about real-world manufacturing problems and solutions was a smart move. These videos killed it on LinkedIn, easily outperforming their static image ads.

The messaging hammered home Lonza’s value prop: they help you speed up drug development and lower risk. You saw lines like “From lab to life-changing therapy, faster” and “Precision manufacturing, unparalleled expertise” everywhere. They kept the tone informative and trustworthy instead of using a lot of salesy hype. That’s the right call in a field where scientific proof means everything.

Performance Metrics and Analysis

Over six months, the “Biologics Breakthrough” campaign brought in 6,500 leads at an average CPL of $210. Now, that CPL might make a B2C marketer’s eyes water, but for high-value B2B leads in this specific pharma niche, it’s a solid number. The campaign’s return on ad spend (ROAS) hit 3.5:1, which means for every dollar in, they got $3.50 back in revenue. That ROAS confirms the campaign was attracting the right kind of prospects who turned into real business.

Channel-Specific Performance

• LinkedIn Ads:
  • Impressions: 15 million
  • Click-Through Rate (CTR): 1.8%
  • Conversions (Whitepaper Downloads/Consultation Requests): 4,200
  • Cost Per Conversion: $171.43
  • Key Insight: The video ads on LinkedIn were the real winners, pulling a 2.5% CTR compared to just 1.2% for static images. This is what made them shift the budget around mid-campaign.
• Programmatic Display (The Trade Desk):
  • Impressions: 22 million
  • CTR: 0.35%
  • Conversions: 1,800
  • Cost Per Conversion: $333.33
  • Key Insight: Even with a low CTR, programmatic was doing the heavy lifting for brand awareness and retargeting. Audiences who were retargeted after seeing a display ad converted at 2x the rate when they saw a LinkedIn ad later.
• Targeted Email Marketing:
  • Emails Sent: 50,000 (to an opted-in list and people who downloaded content)
  • Open Rate: 28%
  • Click-to-Open Rate (CTOR): 10%
  • Conversions: 500 (direct consultation requests)
  • Cost Per Conversion: N/A (these were nurtured leads, so no direct ad cost)
  • Key Insight: The email nurture sequence worked well, especially the third email in the series, which converted an impressive 20% of openers into consultation requests.

What Worked Well

The campaign’s biggest win came from its hyper-focused targeting. Lonza used LinkedIn’s detailed filters to get right in front of decision-makers which cut down on wasted ad spend. Mixing high-level thought leadership with clear, direct-response CTAs was also a brilliant move. They gave away real value with expert content, earning trust before they ever asked for a meeting. And that data-driven decision to pour more money into video on LinkedIn? It paid off by boosting engagement and lowering their conversion costs.

Lonza also nailed something a lot of B2B marketers trip over: the hand-off from marketing to sales. Every lead that came in from the campaign was instantly sent to the right sales rep, complete with all the context, what content they downloaded, their job title, etc. This made the first sales call a lot warmer and helped shorten the sales cycle, which is a huge deal when you’re talking about transactions this big.

What Didn’t Work as Expected

The first programmatic display campaigns were a bit of a miss. They targeted a wide audience of “pharma industry professionals,” and while they got tons of impressions, the CTR was low and the cost per conversion was high. The takeaway? The messaging didn’t land for a general audience who couldn’t see how it connected to their specific job. We also saw that landing pages with generic stock photos tanked compared to ones showing real Lonza labs and scientists. Authenticity in this industry isn’t just a buzzword. It’s a requirement.

In hindsight, their initial video budget was too small. The performance was there from the start, and they could’ve been even more efficient if they’d bet bigger on video from day one. It’s a classic lesson: when the early data shows you a clear winner, you have to be ready to double down, even if it messes with your original plan.

Optimization Steps Taken

After reviewing the first three months of data, they made some smart changes:

1. Budget Reallocation: They pulled 20% of the programmatic budget and pushed it into LinkedIn video ads. This move increased their total video spend by 40% and immediately dropped their average cost per conversion on LinkedIn by 15%.
2. Refined Programmatic Targeting: They stopped the broad targeting and tightened up their programmatic audiences, focusing on specific company lists and better-performing lookalike audiences from their CRM. This alone bumped programmatic CTR by 25%.
3. Landing Page A/B Testing: They started A/B testing visuals and CTA copy. It turned out that pages showing their own R&D teams and using a CTA like “Schedule an Expert Consultation” beat generic photos and “Download Now” by a solid 18% conversion lift.
4. Content Refresh: Seeing what topics were resonating, they commissioned two new whitepapers on gene therapy manufacturing. These fresh assets were promoted on their best channels and had a 10% higher download rate than the first batch of content.

Competitive Field Implications

Lonza’s “Biologics Breakthrough” campaign shows they have a deep understanding of the digital pharma game. The fact that they could generate good leads at a decent CPL and get a 3.5:1 ROAS means their strategy is something competitors like Catalent and WuXi Biologics need to be studying. They’ll have to look at their own content plans, especially how they’re using (or not using) video and super-specific targeting on professional networks. Lonza’s success combining expert content with direct lead-gen sets a new standard.

The message is clear: the future is in deep, technical content, not glossy marketing brochures. Pharma decision-makers aren’t looking for fluff. They’re looking for partners who understand their complex problems and can offer real solutions. Your digital strategy has to reflect that. The kind of precision targeting you can do on a platform like LinkedIn means that old “spray and pray” ad buys aren’t just a waste of money, they actively damage your brand’s credibility.

This Lonza campaign is a great playbook for what works in the specialized pharma market. Their mix of targeted content, smart platform choices, and constant data-driven tweaks built a machine that brought in leads and strengthened their brand. If you want to get better at refining your own campaigns, check out our guide on fixing AI Max campaigns for better results.